Ligand Pharmaceuticals Profit Margin

The latest profit margin for LGND is 63.49% as of June 2026. That compares with -40.44% in the prior-year period — up 257.0% year over year. That is above the Healthcare sector average of 13.89%. Investors often review this figure alongside Ligand Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, LGND's profit margin moved from -40.44% to 63.49% — a 257.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ligand Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, LGND currently prints 63.49% for profit margin, while the sector average sits near 13.89%. That is roughly 357.1% above the sector mean. Large gaps often invite a closer look at Ligand Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Ligand Pharmaceuticals converts resources into returns. At 63.49%, LGND may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -40.44% in the prior-year period — up 257.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LGND's profit margin (63.49%), review year-over-year change from -40.44%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.